Navigating FDA regulatory pathways requires precise documentation, deep knowledge of submission requirements, and a QMS that produces audit-ready evidence. From predicate device analysis through final clearance, our RAC-certified team provides end-to-end regulatory submission support.
By Jared Clark, JD, MBA, PMP, CMQ-OE, RAC — Updated March 2026
Every medical device sold in the United States must have either FDA clearance, approval, or a granted authorization before entering the market — unless it qualifies for an exemption. The pathway your device takes to market depends on its classification, risk profile, and whether substantially equivalent predicate devices already exist. Selecting the correct submission pathway is one of the most consequential regulatory decisions a medical device company will make, because it determines the type of evidence required, the review timeline, the user fee amount, and the post-market obligations that follow clearance or approval.
The FDA classifies medical devices into three risk-based categories: Class I (low risk, most exempt from premarket review), Class II (moderate risk, typically cleared via 510(k)), and Class III (high risk, requiring PMA approval). However, this classification framework is only the starting point. Novel devices that lack predicates, combination products, Software as a Medical Device (SaMD), and devices with new intended uses all require careful pathway analysis that goes well beyond simple classification lookup.
A robust ISO 13485 quality management system is the foundation that supports every FDA submission pathway. The design controls documentation, risk management file, and verification and validation data generated through your QMS become the technical evidence that populates your regulatory submission. Organizations that treat quality system compliance and regulatory submissions as separate activities invariably produce submissions with gaps, inconsistencies, and traceability failures that trigger FDA Additional Information (AI) requests and delay clearance.
200+
Clients Served
100%
First-Time Audit Pass Rate
RAC
Regulatory Affairs Certified
Pathway Comparison
Each FDA regulatory pathway has distinct requirements for evidence, review timelines, and post-market obligations. Understanding these differences is critical for regulatory strategy planning.
| Characteristic | 510(k) | De Novo | PMA |
|---|---|---|---|
| Device Risk Level | Low–Moderate (Class II) | Low–Moderate (Novel) | High (Class III) |
| Predicate Required | Yes — substantial equivalence | No — novel classification | No — safety/efficacy evidence |
| Evidence Standard | Substantial equivalence | Reasonable assurance | Valid scientific evidence |
| MDUFA Review Goal | 90 FDA days (standard) | 150 FDA days | 180 FDA days |
| Clinical Data | Sometimes required | Often required | Always required |
| Post-Clearance Outcome | 510(k) clearance | De Novo grant + new regulation | PMA approval order |
The 510(k) premarket notification is the most common FDA regulatory submission pathway, used for approximately 3,000–4,000 device clearances annually. A 510(k) demonstrates that a new medical device is substantially equivalent (SE) to a legally marketed predicate device — meaning it has the same intended use and either the same technological characteristics, or different characteristics that do not raise new questions of safety and effectiveness. The 510(k) pathway applies to most Class II devices and to Class I devices that are not exempt from premarket notification.
The predicate device analysis is the strategic cornerstone of every 510(k) submission. Selecting the right predicate — or combination of predicates for split-predicate strategies — determines the scope of testing required and the strength of your substantial equivalence argument. Predicate research should begin during the earliest stages of product development, not after design freeze. The FDA's 510(k) database, product codes, classification regulations, and Summary of Safety and Effectiveness Data (SSED) documents are essential resources for predicate identification and competitive intelligence.
The De Novo classification request provides a regulatory pathway for novel medical devices that are low-to-moderate risk but lack a substantially equivalent predicate device. Before the De Novo pathway existed, these devices would default to Class III (requiring PMA), even when their risk profile did not warrant the most rigorous approval pathway. De Novo allows the FDA to classify a novel device into Class I or Class II with appropriate special controls, and the granted De Novo device becomes a predicate for future 510(k) submissions by other manufacturers.
De Novo submissions have increased significantly in recent years, particularly for Software as a Medical Device (SaMD), AI/ML-enabled devices, digital health technologies, and devices incorporating novel sensor technologies. The De Novo pathway requires more extensive evidence than a 510(k) because there is no predicate comparison — instead, the applicant must demonstrate that the device provides a reasonable assurance of safety and effectiveness and propose the special controls that will serve as the regulatory framework for the new device type. These proposed special controls become binding requirements if the De Novo is granted.
Premarket Approval (PMA) is the most stringent FDA regulatory pathway, reserved for Class III high-risk medical devices that sustain or support human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. PMA requires valid scientific evidence demonstrating a reasonable assurance of safety and effectiveness — a significantly higher evidentiary standard than the substantial equivalence required for 510(k) clearance. Examples of Class III devices include implantable cardiac defibrillators, coronary stents, total hip replacements, and high-risk in vitro diagnostic tests.
PMA applications typically include extensive clinical trial data from well-controlled investigations, comprehensive non-clinical testing, detailed manufacturing information, and a complete summary of the device's safety and effectiveness data. The PMA review process involves an FDA advisory committee panel meeting for most original PMA applications, during which external clinical and scientific experts evaluate the evidence and provide recommendations to the FDA. Post-approval requirements for PMA devices are also more extensive than for 510(k)-cleared devices, often including post-approval studies (PAS), annual reports, and more restrictive change requirements under PMA supplements.
The Design History File is the compilation of all records describing the design history of the finished medical device, as required by ISO 13485 Clause 7.3 and FDA 21 CFR 820.30. For FDA regulatory submissions, the DHF serves as the master source of technical evidence — the performance testing data, risk management documentation, verification and validation records, and design traceability that populate the submission. A well-organized DHF makes submission preparation dramatically faster and more defensible, because every piece of evidence traces back to a documented design input and a planned verification or validation activity.
The DHF must be distinguished from the Device Master Record (DMR), which contains the current production specifications, and the Device History Record (DHR), which documents the manufacturing history of each production lot. During an FDA inspection following a submission, investigators will often request both the DHF and the DMR to verify that the design was properly controlled and that manufacturing specifications are consistent with the validated design. Organizations that conflate these three records frequently generate audit findings and inspection observations.
Performance testing documentation is the evidentiary backbone of every FDA regulatory submission. The scope and depth of testing depends on the device type, classification, intended use, and applicable FDA guidance documents and consensus standards. At minimum, most submissions require bench testing demonstrating that the device meets its design output specifications, biocompatibility evaluation per ISO 10993 for all patient-contacting materials, and electrical safety and electromagnetic compatibility testing per the IEC 60601 series for electrically powered devices.
Biocompatibility testing under ISO 10993 evaluates the biological response to medical device materials based on the nature and duration of patient contact. The biocompatibility evaluation begins with a biological evaluation plan that identifies the required endpoints — which may include cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation effects, and hemocompatibility, depending on the device's contact category. FDA expects manufacturers to follow the risk-based approach described in ISO 10993-1, using existing data and chemical characterization before defaulting to animal testing. Biocompatibility data must be generated on the final, finished form of the device, including the effects of manufacturing processes, sterilization, and any coatings or surface treatments.
MDUFA V Performance Goals
Understanding MDUFA review timelines helps you plan your regulatory strategy and set realistic market entry expectations. A complete, well-prepared submission is the single most effective way to minimize review time.
Standard 510(k): 90 FDA-day review goal. Special 510(k): 30 FDA-day review goal for modifications to the submitter's own cleared device. Abbreviated 510(k): similar timeline with reliance on guidance documents or special controls. The clock stops during Additional Information (AI) response periods, which can add weeks or months to total elapsed time.
De Novo classification requests have a 150 FDA-day review goal. Given the novelty of these devices and the need to establish special controls, De Novo reviews frequently involve multiple rounds of interactive review with the FDA. Pre-submission (Q-Sub) meetings are strongly recommended to align on the classification rationale, proposed special controls, and clinical evidence strategy before filing.
Original PMA applications have a 180 FDA-day review goal for first action. Most original PMAs undergo advisory committee panel review, adding 60–90 calendar days. PMA supplements for device modifications vary: 180 days for panel-track supplements, 135 days for 180-day supplements, and 30 days for real-time PMA supplements. Pre-submission engagement with FDA is essential for PMA-track devices.
With the FDA's Quality Management System Regulation (QMSR) incorporating ISO 13485:2016 by reference, maintaining a compliant quality management system is no longer merely best practice — it is a regulatory prerequisite for any FDA submission. The QMSR replaces the legacy 21 CFR 820 framework and directly references ISO 13485 for quality system requirements, including management responsibility, resource management, product realization, and measurement and analysis. Organizations that have already implemented ISO 13485 are well-positioned for QMSR compliance with minimal additional effort.
The practical connection between your QMS and FDA submissions is direct and bidirectional. Your ISO 13485 implementation produces the documented procedures, work instructions, and records that FDA inspectors will evaluate during pre-approval inspections (for PMA devices) or routine surveillance inspections. Your design controls produce the DHF evidence that populates the submission. Your risk management process produces the ISO 14971 risk management file that supports the safety analysis in your submission. Your CAPA system, complaint handling, and post-market surveillance processes demonstrate the organizational capability to monitor and respond to safety signals after the device reaches the market.
Design Controls (Clause 7.3)
DHF provides V&V data, risk analysis, and design traceability for the submission's technical sections.
Purchasing Controls (Clause 7.4)
Supplier qualification records and material certificates support biocompatibility and component traceability claims.
Production & Service (Clause 7.5)
Manufacturing process validation (IQ/OQ/PQ) and sterilization validation records are required for PMA manufacturing sections.
CAPA & Complaint Handling (Clause 8)
Post-market surveillance capability demonstrated through CAPA and complaint handling procedures satisfies FDA post-clearance expectations.
End-to-End Support
From initial pathway analysis through FDA clearance or approval, our RAC-certified regulatory team provides the strategic guidance and technical documentation expertise that medical device companies need to navigate the FDA submission process efficiently and successfully.
Classification determination, pathway selection (510(k)/De Novo/PMA), predicate device research, and pre-submission (Q-Sub) preparation.
Complete submission drafting including device description, SE comparison, performance testing summaries, labeling review, and eSTAR formatting.
Biocompatibility evaluation planning (ISO 10993), performance testing protocols, software documentation (IEC 62304), and test lab coordination.
Pre-submission meeting preparation, AI response drafting, reviewer interaction management, and appeal strategy when needed.
Ensuring your ISO 13485 quality system produces submission-ready documentation, with DHF organization and QMSR gap analysis.
EU MDR Technical Documentation, Health Canada MDL, and other international market access coordination alongside FDA submissions.
A medical device startup with a novel in-vitro diagnostic platform engaged our team for end-to-end regulatory submission support. We conducted predicate research identifying an optimal split-predicate strategy, developed the performance testing plan, authored the complete 510(k) submission, and managed the FDA interactive review process. The submission received SE determination with zero AI requests — clearing the device in 67 FDA days. The same DHF documentation supported subsequent ISO 13485 certification with zero major nonconformities.
View Case Studies →FDA regulatory submissions consulting is a core specialty within Certify Consulting. For a complete view of all ISO certification services — including ISO 9001, ISO 14001, ISO 27001, ISO 42001, and more — visit the hub.
Expert answers to common questions about 510(k), De Novo, PMA pathways, and regulatory submission strategy.
Whether you need 510(k) predicate analysis, De Novo classification strategy, or PMA application support, our RAC-certified team provides end-to-end regulatory submission consulting. Schedule a free consultation to discuss your device and pathway.
No commitment required. 200+ clients served with a 100% first-time audit pass rate.
JD, MBA, PMP, CMQ-OE, RAC
Jared Clark is an FDA regulatory submissions consultant and ISO 13485 quality expert with deep expertise in 510(k), De Novo, and PMA submission preparation. His Regulatory Affairs Certification (RAC) from RAPS represents the gold standard credential for medical device regulatory professionals, qualifying him to develop and execute comprehensive regulatory strategies from pathway analysis through FDA clearance. With 200+ medical device clients and a 100% first-time audit pass rate, Jared has helped companies across the device spectrum navigate FDA regulatory submissions efficiently and successfully.
Integrated quality management and FDA regulatory pathway support for 510(k) premarket notification submissions.
ISO 13485 Clause 7.3 design controls, DHF structure, verification, validation, and FDA 21 CFR 820 alignment.
ISO 14971 risk management for medical devices — FMEA, fault tree analysis, risk-benefit analysis, and ISO 13485 integration.